Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

9.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.5K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

7.2K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
7.2K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.4K
Detailed Structure and Function of Lymph Nodes01:23

Detailed Structure and Function of Lymph Nodes

13.3K
Lymph nodes are bean-shaped structures that cluster along the lymphatic vessels in the inguinal, axillary, and cervical regions. Each node is divided into compartments by a capsule that extends trabeculae inward.
From a histological perspective, lymph nodes can be split into two main areas: the superficial cortex and the deep medulla. The outer cortex is populated by dendritic cells, macrophages, and B lymphocytes, which are densely packed into follicles. When these B-lymphocytes are presented...
13.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Kidney Involvement in Sarcoidosis-Lymphoma Syndrome: A Report of Two Cases.

CEN case reports·2026
Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026
Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026
Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

9.3K

Non-Hodgkin's lymphomas, version 4.2014.

Andrew D Zelenetz, Leo I Gordon, William G Wierda

    Journal of the National Comprehensive Cancer Network : JNCCN
    |September 6, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Mantle cell lymphoma (MCL), a type of non-Hodgkin's lymphoma (NHL), has specific treatment guidelines. Early-stage MCL may be treated with radiation, while advanced stages benefit from chemoimmunotherapy or targeted therapies like ibrutinib.

    More Related Videos

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
    10:52

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

    Published on: March 30, 2018

    10.6K
    Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
    07:17

    Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

    Published on: August 23, 2024

    1.8K

    Related Experiment Videos

    Last Updated: Apr 24, 2026

    Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
    08:53

    Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

    Published on: June 10, 2017

    9.3K
    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
    10:52

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

    Published on: March 30, 2018

    10.6K
    Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
    07:17

    Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

    Published on: August 23, 2024

    1.8K

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Guidelines

    Background:

    • Non-Hodgkin's lymphomas (NHL) are diverse lymphoproliferative disorders.
    • Mantle cell lymphoma (MCL) comprises about 6% of new NHL diagnoses.
    • MCL originates from B, T, or natural killer cells.

    Purpose of the Study:

    • To outline the National Comprehensive Cancer Network (NCCN) Guidelines for NHL.
    • To detail the diagnosis and management of MCL.
    • To provide evidence-based recommendations for MCL treatment.

    Main Methods:

    • Review of NCCN Guidelines for NHL.
    • Synthesis of current treatment approaches for MCL.
    • Inclusion of newly approved therapies.

    Main Results:

    • Early-stage MCL: Radiation therapy with or without systemic therapy.
    • Advanced-stage MCL: Rituximab-based chemoimmunotherapy with high-dose therapy and autologous stem cell rescue (HDT/ASCR).
    • Alternative for non-HDT/ASCR candidates: Induction therapy with rituximab maintenance.
    • Relapsed/refractory MCL: Ibrutinib (Bruton tyrosine kinase inhibitor) approved.

    Conclusions:

    • Treatment strategies for MCL are stage-dependent.
    • Chemoimmunotherapy and HDT/ASCR are key for advanced MCL.
    • Targeted therapies like ibrutinib offer new options for relapsed/refractory disease.